Impact of Tight Glycaemic Control in Acute Myocardial Infarction

Impact of Tight Glycaemic Control With Insulin on Novel Vascular Disease Risk Factors and Myocardial Function and Perfusion in Acute Myocardial Infarction Patients With Hyperglycaemia

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00237471

Enrollment

Registered

2005-10-12

Start date

2005-10-31

Completion date

2006-05-31

Last updated

2011-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia, Myocardial Infarct

Keywords

Acute Myocardial Infarction, Hyperglycaemia, Insulin Infusion

Brief summary

To determine whether tight glycaemic control with insulin improves myocardial function and myocardial perfusion (measured by myocardial contrast echocardiography) and novel vascular risk factors in patients with acute myocardial infarction and hyperglycaemia.

Detailed description

We will randomise patients with acute myocardial infarction and blood glucose levels (BGLs) \>=10mmol/L within 24 hours of pain onset, to either tight glucose control (aiming BGLs 4.5 - 7mmol/L) with an insulin infusion (for 24 hours) followed by subcutaneous insulin or standard control (BGL 6 - 12mmol/L) without the use of an insulin infusion. Serial myocardial contrast echocardiography will measure changes in myocardial perfusion and function from baseline to 3 months between each group. We will also measure changes in inflammatory and endothelial markers over this time to see whether tight glucose control improves these surrogate endpoints.

Interventions

DRUGInsulin (tight blood glucose control)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>=18years * Acute Myocardial Infarction * Blood Glucose Level \>=10mmol/L * Wall motion abnormality on baseline echocardiogram

Exclusion criteria

* Active infection/inflammation * Cardiac shunt * Cognitive Impairment * Insulin allergy

Design outcomes

Primary

Measure	Time frame
Difference in the change in wall motion score index between admission, day 3-5 and after 3 months in the two treatment arms.	—

Secondary

Measure	Time frame
Changes in inflammatory/endothelial markers and myocardial perfusion from admission, day 3-5 and after 3 months between the two treatment arms	—

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026